nSMase3: Novel neutral Sphingomyelinase and its use for diagnostics andtherapy with focus on heart muscle diseases and male fert
A novel human TNF-responsible neutral phingomyelinase enzyme (nSMase3) has been identified. Furthermore, the invention relates to the use of nSMase3 as pharmaceutical and diagnostic target
and to appropriate test systems. The human enzyme was identified by screening database sequences with up to now unknow n function w ith a short sequence derived from a bovine neutral sphingomyelinase. The identified nSMase3 shows no significant homologies to the well-know n human neutral sphingomyelinases type 1 and type 2.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Single-Celled Heroes: Foraminifera’s Power to Combat Ocean Phosphate Pollution
So-called foraminifera are found in all the world’s oceans. Now an international study led by the University of Hamburg has shown that the microorganisms, most of which bear shells, absorb…
Humans vs Machines—Who’s Better at Recognizing Speech?
Are humans or machines better at recognizing speech? A new study shows that in noisy conditions, current automatic speech recognition (ASR) systems achieve remarkable accuracy and sometimes even surpass human…
Not Lost in Translation: AI Increases Sign Language Recognition Accuracy
Additional data can help differentiate subtle gestures, hand positions, facial expressions The Complexity of Sign Languages Sign languages have been developed by nations around the world to fit the local…